First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
Conclusions
These results confirm the favorable safety and efficacy profile of 177Lu-PSMA, even up to 6 treatment cycles. Therefore, 177Lu-PSMA seems a promising therapeutic strategy for metastatic castration-resistant PCa patients. However, randomized controlled trials are warranted to obtain robust data.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Hematology | Netherlands Health | Nuclear Medicine | Pain | Prostate Cancer | Study | Toxicology | Xerostomia